Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy – Beyond the Abstract

detection on PET/CT of sub-clinical immune-related adverse events, clinical impact of inflammatory fluorodeoxyglucose positron emission tomography uptake, PURE-01 clinical trial, PET/CT immune-related adverse events before radical cystectomy, role of Fluorodeoxyglucose Positron Emission Tomography.

Read the full article here

Source: www.urotoday.com

Categories: General Medicine News, Latest Headlines

Tags: BeyondTheAbstract, BladderCancer

Tweets with this article

UroToday.com

Incidence and clinical impact of inflammatory fluorodeoxyglucose PET uptake after neoadjuvant pembrolizumab in patients with organ-confined #BladderCancer undergoing radical cystectomy. #BeyondTheAbstract with @LauraLmar89 and @AndreaNecchi on UroToday > https://t.co/c9Em69o7L5 https://t.co/orONxurBJQ

PSMA and RLT: The VISION and TheraP Trials “Presentation” – Michael Morris

At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy…

UroToday.com April 19, 2024

The Efficacy of Sequential Gemcitabine and Docetaxel in Intermediate-Risk Non Muscle Invasive Bladder Cancer – Expert Commentary

Non Muscle Invasive Bladder Cancer (NMIBC), Sequential Gemcitabine and Docetaxel, Bacillus Calmette-Guérin (BCG), Gem/Doce. global BCG supply shortage, radical cystectomy, efficacy of sequential Gem/Doce treatment…

UroToday.com April 19, 2024

Operationalizing Blue Light in Your Practice – Gautam Jayram

Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent,…

UroToday.com April 19, 2024

Nadofaragene Firadenovec: Adding to the Treatment Regimen Protocol – Joshua Meeks

Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA…

UroToday.com April 19, 2024

AMG 509’s Potential in Prostate Cancer Therapy – Michael Morris

Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal…

UroToday.com April 19, 2024

The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America

prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer,…

UroToday.com April 19, 2024

Research Reveals How Metabolic Rewiring Enables “Persister” Cancer Cells to Resist Death and Treatment – Asmaa El-Kenawi

Asmaa El-Kenawi discusses her group’s research on therapeutic resistance in cancer, particularly focusing on the role of methionine in driving resistance. Published in “Cancer Research,”…

UroToday.com April 19, 2024

The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer – Matthew Abramowitz

Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…

UroToday.com April 19, 2024

Circulating Tumor DNA Based Minimal Residual Disease Detection and Adjuvant Treatment Decision-Making for Muscle-Invasive Bladder Cancer Guided by Modern Clinical Trials – Beyond the Abstract

bladder cancer, Circulating Tumor DNA (ctDNA), Residual Disease Detection, imvigor010 study, immunotherapy, adjuvant therapy, urine tumor DNA markers, treatment of invasive bladder cancer.

UroToday.com April 19, 2024

Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk – Tanya Stoyanova

Tanya Stoyanova discusses research on Trop2’s role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study…

UroToday.com April 19, 2024

Related Articles